AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23022496 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopists with at least 20 polypectomies
Number of subjects: 1427
Study 23023470 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels
Number of subjects: 62
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and Sleep Apnea (SA)
Number of subjects: 716
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression alone
Number of subjects: 716
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Apnea alone
Number of subjects: 716
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither depression nor SA
Number of subjects: 716
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Apnea in patients with depression
Number of subjects: 716
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in patients with Sleep Apnea
Number of subjects: 716
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Apnea in patients without depression
Number of subjects: 716
Study 23023681 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in patients without Sleep Apnea
Number of subjects: 716
Study 23024237 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 20
Study 23025537 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily (MMPI)
Number of subjects: 39
Study 23025537 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 39
Study 23026055 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA expression profiling in cSCC tumors
Number of subjects: 7
Study 23026055 — intervention group
Group type: COMPARATOR
Intervention: Adjacent healthy skin biopsies as control
Number of subjects: 7
Study 23026499 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Symptom Utility Index (ASUI)
Number of subjects: 1648
Study 23028556 — intervention group
Group type: EXPERIMENTAL
Intervention: SARP simplified algorithm
Number of subjects: 471
Study 23031215 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion treatment
Number of subjects: 3940
Study 23031215 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at day 60 (±10)
Number of subjects: 3940
Study 23031283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral renal denervation
Number of subjects: 7
Study 23031290 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 23031290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no statins)
Number of subjects: 0
Study 23031624 — intervention group
Group type: EXPERIMENTAL
Intervention: rilonacept 160 mg weekly (adults) or 2.2 mg/kg weekly (pediatrics, up to 160 mg)
Number of subjects: 101
Study 23032196 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry patients
Number of subjects: 697
Study 23032196 — intervention group
Group type: COMPARATOR
Intervention: RCT patients
Number of subjects: 697
Study 23032197 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NT-proBNP levels
Number of subjects: 5597
Study 23032197 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 5597
Study 23032420 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cidofovir 1% applied for six 2-week cycles
Number of subjects: 33
Study 23032420 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cidofovir 1%
Number of subjects: 33
Study 23032625 — intervention group
Group type: EXPERIMENTAL
Intervention: Assay-directed site-specific treatment
Number of subjects: 289
Study 23032625 — intervention group
Group type: EXPERIMENTAL
Intervention: Assay-directed site-specific treatment (responsive tumor types)
Number of subjects: 289
Study 23032625 — intervention group
Group type: EXPERIMENTAL
Intervention: Assay-directed site-specific treatment (resistant tumor types)
Number of subjects: 289
Study 23032625 — intervention group
Group type: COMPARATOR
Intervention: Assay-directed site-specific treatment (comparison of responsive vs resistant)
Number of subjects: 289
Study 23033266 — intervention group
Group type: EXPERIMENTAL
Intervention: IPH2101 (anti-KIR antibody) administered intravenously every 28 days in 7 dose-escalated cohorts (0.0003-3 mg/kg) for up to 4 cycles.
Number of subjects: 32
Study 23033395 — intervention group
Group type: EXPERIMENTAL
Intervention: Reattached retina
Number of subjects: 28
Study 23033932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse dose imatinib and weekly paclitaxel
Number of subjects: 34
Study 23034133 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (increasing doses, 72 hours incubation)
Number of subjects: 20
Study 23034133 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from patients with metformin intoxication
Number of subjects: 20
Study 23034133 — intervention group
Group type: COMPARATOR
Intervention: Saline (control for in vitro experiments)
Number of subjects: 20
Study 23034133 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control for ex vivo experiments)
Number of subjects: 20
Study 23034910 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing at baseline
Number of subjects: 1636
Study 23034910 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of mild cognitive impairment (MCI)
Number of subjects: 1636
Study 23034910 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin score 0-1 and Barthel score = 100
Number of subjects: 1636
Study 23034910 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age, male sex, less education, poststroke disability, impaired activities of daily living
Number of subjects: 1636
Study 23034963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-screening using MUST
Number of subjects: 205
Study 23035760 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice accreditation program focusing on cardiovascular risk management (intervention group, n = 35 practices)
Number of subjects: 70
Study 23035760 — intervention group
Group type: COMPARATOR
Intervention: Control group focusing on other domains in the first year of the program (control group, n = 35 practices)
Number of subjects: 70
Study 23035760 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice accreditation program (intervention group)
Number of subjects: 70
Study 23036014 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE intervention (technology-enabled participation in IDT meetings)
Number of subjects: 84
Study 23036135 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired cerebrovascular autoregulation (AR) measured by Mx index
Number of subjects: 30
Study 23036135 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of sepsis-associated delirium (SAD) using CAM-ICU
Number of subjects: 30
Study 23036135 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of impaired AR at day 1 with SAD incidence at day 4
Number of subjects: 30
Study 23036475 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 20
Study 23036928 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stem cells
Number of subjects: 0
Study 23039868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management Profile for Type 2 Diabetes (SMP-T2D) administered with retest one week later (Study 1)
Number of subjects: 240
Study 23039868 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management Profile for Type 2 Diabetes (SMP-T2D) administered with 24-week follow-up after medication change (Study 2)
Number of subjects: 240
Study 23039868 — intervention group
Group type: EXPERIMENTAL
Intervention: SMP-T2D measures
Number of subjects: 240
Study 23040202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body lift procedure
Number of subjects: 50
Study 23040326 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatments were platinum-based combinations with pemetrexed (36.3%), gemcitabine (23.0%), vinorelbine (19.2%), taxanes (18.9%), or other (2.6%), with concurrent targeted agents in 8.4% of patients (mainly bevacizumab, 7.3%).
Number of subjects: 1567
Study 23040326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed cohort
Number of subjects: 1567
Study 23040326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab cohort
Number of subjects: 1567
Study 23040326 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology testing
Number of subjects: 1567
Study 23040326 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC and predictive biomarkers
Number of subjects: 1567
Study 23040326 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR mutation status testing
Number of subjects: 1567
Study 23040435 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 (cyclophosphamide, doxorubicin, vincristine, and prednisone every 14 days)
Number of subjects: 1113
Study 23040435 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-21 (cyclophosphamide, doxorubicin, vincristine, and prednisone every 21 days)
Number of subjects: 1113
Study 23040435 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to G-CSF guidelines
Number of subjects: 1113
Study 23040435 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy delivery
Number of subjects: 1113
Study 23040438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat combined with bortezomib
Number of subjects: 34
Study 23041322 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Number of subjects: 73
Study 23041322 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 73
Study 23041322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 73
Study 23041322 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation
Number of subjects: 73
Study 23041322 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet count
Number of subjects: 73
Study 23041322 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen length corrected for patient's height
Number of subjects: 73
Study 23041322 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 73
Study 23041588 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks
Number of subjects: 65
Study 23041588 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks in confirmed KRAS wild-type population
Number of subjects: 65
Study 23041588 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks in patients with no identified mutation
Number of subjects: 65
Study 23041595 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG uptake in subcutaneous adipose tissue (SAT) of the extremities
Number of subjects: 0
Study 23041595 — intervention group
Group type: EXPERIMENTAL
Intervention: Extremity SAT FDG uptake
Number of subjects: 0
Study 23042966 — intervention group
Group type: EXPERIMENTAL
Intervention: High persistent EBV load
Number of subjects: 106
Study 23042966 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EBV load prior to PTLD
Number of subjects: 106
Study 23042966 — intervention group
Group type: EXPERIMENTAL
Intervention: EBV high-risk (D(+)/R(-)) serostatus
Number of subjects: 106
Study 23042966 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HLA-DR7
Number of subjects: 106
Study 23042966 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity of immunosuppressive therapy
Number of subjects: 106
Study 23042980 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 2737
Study 23042980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study 23042980 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone vs Placebo
Number of subjects: 2737
Study 23043036 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 20
Study 23043671 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Client (SC) survey
Number of subjects: 55
Study 23043671 — intervention group
Group type: COMPARATOR
Intervention: Conspicuous Observation (CO) survey
Number of subjects: 55
Study 23043671 — intervention group
Group type: COMPARATOR
Intervention: IMCI-trained health workers (CO vs SC)
Number of subjects: 55
Study 23043671 — intervention group
Group type: COMPARATOR
Intervention: Non-IMCI trained health workers (CO vs SC)
Number of subjects: 55
Study 23043852 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 16
Study 23044556 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D gradient-echo (3DGRE)
Number of subjects: 95
Study 23044556 — intervention group
Group type: EXPERIMENTAL
Intervention: short tau inversion recovery (STIR)
Number of subjects: 95
Study 23044556 — intervention group
Group type: COMPARATOR
Intervention: 3DGRE and STIR
Number of subjects: 95
Study 23044556 — intervention group
Group type: COMPARATOR
Intervention: mathematical algorithm (MATH)
Number of subjects: 95
Study 23044556 — intervention group
Group type: COMPARATOR
Intervention: histogram segmentation method (HSM)
Number of subjects: 95
Study 23044629 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus pregnancies
Number of subjects: 0
Study 23045466 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal nerve ablation
Number of subjects: 12
Study 23045577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (PCI-32765) at doses up to 12.5 mg/kg per day
Number of subjects: 56
Study 23045580 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 20 mg/m2 on days 1 and 15, every 28 days (maximum of six cycles)
Number of subjects: 49
Study 23046968 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Number of subjects: 20
Study 23047045 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zoledronic acid (4 mg every 6 months for 5 years)
Number of subjects: 1065
Study 23047045 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid (initiated for fracture or on-study BMD decrease)
Number of subjects: 1065
Study 23047045 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate zoledronic acid
Number of subjects: 1065
Study 23047045 — intervention group
Group type: COMPARATOR
Intervention: Delayed zoledronic acid
Number of subjects: 1065
Study 23047130 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of coronary heart disease (CHD)
Number of subjects: 1314
Study 23047130 — intervention group
Group type: COMPARATOR
Intervention: Patients without a history of coronary heart disease (CHD)
Number of subjects: 1314
Study 23047130 — intervention group
Group type: EXPERIMENTAL
Intervention: Most complex patients
Number of subjects: 1314
Study 23047130 — intervention group
Group type: COMPARATOR
Intervention: Least complex patients
Number of subjects: 1314
Study 23047130 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall risk factor control
Number of subjects: 1314
Study 23047301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate (20 ml kg)
Number of subjects: 10
Study 23047301 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (10 ml kg)
Number of subjects: 10
Study 23047301 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ringer's acetate and hydroxyethyl starch
Number of subjects: 10
Study 23047301 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall measurement
Number of subjects: 10
Study 23047301 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion fluid type
Number of subjects: 10
Study 23048170 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory infection consultation
Number of subjects: 11208
Study 23048170 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus circulation and influenza-like illness
Number of subjects: 11208
Study 23049090 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT-CNTF implant (NT-501)
Number of subjects: 10
Study 23049701 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life decisions (EOLD)
Number of subjects: 224
Study 23049701 — intervention group
Group type: COMPARATOR
Intervention: EOLD performance after law enactment
Number of subjects: 224
Study 23049701 — intervention group
Group type: EXPERIMENTAL
Intervention: EOLD-associated documentation
Number of subjects: 224
Study 23050517 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centred Communication Intervention
Number of subjects: 60
Study 23051772 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted LC-MS/MS for measuring amino acids and dipeptides
Number of subjects: 30
Study 23051966 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg orally twice a day until disease progression, death, or unacceptable adverse events.
Number of subjects: 172
Study 23052535 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal prehabilitation program (exercise, nutritional counseling, protein supplementation, anxiety reduction)
Number of subjects: 42
Study 23052535 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodal prehabilitation program
Number of subjects: 42
Study 23052535 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard surgical care)
Number of subjects: 42
Study 23052713 — intervention group
Group type: EXPERIMENTAL
Intervention: mfPERG
Number of subjects: 25
Study 23052713 — intervention group
Group type: EXPERIMENTAL
Intervention: FD-OCT
Number of subjects: 25
Study 23052713 — intervention group
Group type: EXPERIMENTAL
Intervention: mfPERG and OCT
Number of subjects: 25
Study 23053555 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 690
Study 23053683 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (20 mg every other week for patients <30 kg; 40 mg every other week for patients ≥30 kg) with concomitant methotrexate allowed (≤10 mg/m² per week)
Number of subjects: 25
Study 23053683 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 25
Study 23053683 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with MTX
Number of subjects: 25
Study 23053847 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caries-risk scenario
Number of subjects: 189
Study 23053847 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-caries-risk scenario
Number of subjects: 189
Study 23054206 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC102 at 15, 30, 60 or 100 mg/m(2)/d
Number of subjects: 28
Study 23054206 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC102 combined with standard-dose pemetrexed
Number of subjects: 28
Study 23054206 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC102 at 60 mg/m(2)/d for 4 days with pemetrexed
Number of subjects: 28
Study 23054208 — intervention group
Group type: EXPERIMENTAL
Intervention: Foretinib 80 mg once daily
Number of subjects: 37
Study 23054338 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vancomycin (OV)
Number of subjects: 14
Study 23055034 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene nerve block
Number of subjects: 30
Study 23055034 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge
Number of subjects: 30
Study 23056238 — intervention group
Group type: EXPERIMENTAL
Intervention: BSAM2/Alhydrogel®+CPG 7909 (40 µg total protein)
Number of subjects: 30
Study 23056238 — intervention group
Group type: EXPERIMENTAL
Intervention: BSAM2/Alhydrogel®+CPG 7909 (160 µg total protein)
Number of subjects: 30
Study 23056238 — intervention group
Group type: EXPERIMENTAL
Intervention: BSAM2/Alhydrogel®+CPG 7909 (both doses)
Number of subjects: 30
Study 23056467 — intervention group
Group type: EXPERIMENTAL
Intervention: External counterpulsation therapy (ECP) at high inflation pressure (300 mmHg)
Number of subjects: 0
Study 23056467 — intervention group
Group type: COMPARATOR
Intervention: External counterpulsation therapy (ECP) at low inflation pressure (80 mmHg)
Number of subjects: 0
Study 23057791 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin (50 or 100 mg once daily at bedtime or 25 or 50 mg twice daily)
Number of subjects: 1723
Study 23057791 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin (100 mg qhs for ≥180 days)
Number of subjects: 1723
Study 23057791 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin
Number of subjects: 1723
Study 23058665 — intervention group
Group type: EXPERIMENTAL
Intervention: EDWARDS INTUITY Valve System
Number of subjects: 152
Study 23059409 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy
Number of subjects: 14
Study 23059454 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM; acupuncture and herbs)
Number of subjects: 168
Study 23059454 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial care (SC)
Number of subjects: 168
Study 23059643 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg twice per day for 3 weeks, increased to 1 g twice per day at week 3 for 3 weeks, then titrated to 2 g twice per day at week 6 for 3 weeks)
Number of subjects: 0
Study 23060463 — intervention group
Group type: COMPARATOR
Intervention: Mid-medullary canal measurement in the lateral view (method MC-90)
Number of subjects: 0
Study 23060463 — intervention group
Group type: EXPERIMENTAL
Intervention: Three alternative methods for measuring volar angulation
Number of subjects: 0
Study 23060463 — intervention group
Group type: EXPERIMENTAL
Intervention: Method SH-Stip for measuring shortening
Number of subjects: 0
Study 23061994 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel
Number of subjects: 0
Study 23061994 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine drops
Number of subjects: 0
Study 23062719 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant, ondansetron, and dexamethasone
Number of subjects: 2813
Study 23062719 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron plus dexamethasone
Number of subjects: 2813
Study 23063203 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program (7 weeks duration)
Number of subjects: 47
Study 23063302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermally injected botulinum neurotoxin type A (BoNT/A), 20 intradermal injections of 0.05 ml in symptomatic areas of lower limbs.
Number of subjects: 27
Study 23063302 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermally injected botulinum neurotoxin type A (BoNT/A)
Number of subjects: 27
Study 23063422 — intervention group
Group type: EXPERIMENTAL
Intervention: 4th-dose of HPV-16/18 AS04-adjuvanted vaccine (024-4DV group)
Number of subjects: 65
Study 23063422 — intervention group
Group type: COMPARATOR
Intervention: 1st-dose of HPV-16/18 AS04-adjuvanted vaccine (024-3DV group)
Number of subjects: 65